Skip to main content
Premium Trial:

Request an Annual Quote

Innovir Labs Is Awarded Patents Covering Use of Oligozymes in Research

Premium

NEW YORK--Innovir Laborato ries here announced last month that it has gained additional US patent rights covering the use of oligozymes in pharmaceutical and genomic research, with four patent applications being allowed and two new patents issued. Innovir already holds three issued patents, eight allowed patent applications, and 20 patent pending applications for oligozyme-based technology.

In addition, the company has corresponding foreign patent rights and has exclusively licensed some related patents from Yale University. "These patents further enhance Innovir's ability to harness oligozymes' strong potential for defining which genes cause certain diseases and which are good targets for drug research," commented Thomas Sharpe, the company's president and CEO. Innovir is a majority-owned subsidiary of VIMRX Pharmaceuticals.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.